Literature DB >> 1349655

Which antihypertensive drugs first--and why!

M H Alderman1.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1349655

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

Review 1.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 2.  Economic factors in the initiation of antihypertensive therapy.

Authors:  I Kawachi
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

3.  Dynamic competition as an exploratory model of healthcare policy for the antihypertensive market.

Authors:  R J Bonk; M J Myers; C H Knowlton; D Sabapathi; W F McGhan
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 4.  Noncompliance with antihypertensive therapy. Economic consequences.

Authors:  T L Skaer; D A Sclar; L M Robison
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 5.  Guidelines for the treatment of hypertension: a critical review.

Authors:  J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

Review 6.  Role of ACE inhibitors in uncomplicated essential hypertension.

Authors:  J I Robertson
Journal:  Br Heart J       Date:  1994-09

7.  Violence as a barrier to compliance for the hypertensive urban African American.

Authors:  R L Fong
Journal:  J Natl Med Assoc       Date:  1995-03       Impact factor: 1.798
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.